Miami, Florida – February 5, 2020 - Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the appointment of Russell Schachar, MD, FRCP(C) as Chief Medical Officer. Dr. Schachar is a practicing child and adolescent psychiatrist, Professor in the Department of Psychiatry at the University of Toronto, and Senior Scientist in the Research Institute at the Hospital for Sick Children in Toronto, Canada where he holds the TD Bank Chair in Child and Adolescent Psychiatry and heads a cognitive neurosciences laboratory which focuses on psychiatric disorders of childhood and adolescence.
“As a highly-regarded researcher and child and adolescent psychiatrist, Russell’s experience in mental health is uniquely suited to Ehave and our PsychedeliTech subsidiary as we continue to evolve our ecosystem,” said Benjamin Kaplan, Chief Executive Officer of Ehave, Inc. “His proven track record for leadership in steering clinical research programs and commitment to better outcomes in mental illness will support our mission of addressing unmet mental health needs for larger patient populations.”
Dr. Schachar initiated an acclaimed clinical-research program in Neuropsychiatry and set up a productive research laboratory at The Hospital for Sick Children (SickKids). During an active career spanning 30 years, his contributions towards Attention Deficit Hyperactivity Disorder (ADHD) and Autism have had significant and far reaching international impact. He remains a leader in the field of child psychopathology, advancing the understanding of brain structure and brain function in mental disorders, traumatic brain injury, and individuals treated for cancer.
Dr. Schachar has contributed to leading texts in Child Psychiatry (Child Psychiatry, Modern Approaches. 4th Edition; Oxford Textbook of Child Psychiatry. Oxford University Press), been invited to present at over 300 lectures at major international meetings, and has been a member of international grant review panels, such as National Institutes of Health, Ontario Mental Health Foundation, Canadian Psychiatric Research Foundation, Health and Welfare Canada and Medical Research Council of Great Britain. Additionally, Dr. Schachar has authored more than 175 articles in top peer-reviewed journals like Lancet, Nature Genetics, American Journal of Psychiatry, Journal of the American Academy of Child and Adolescent Psychiatry, Human Brain Mapping, and the Journal of Child Psychiatry and Psychology. Most recently, Dr. Schachar was inducted into the Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) Hall of Fame for lifetime achievement in ADHD research (2012).
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
For Investor Relations, please contact:
Phone: (623) 261-9046